Mary Tyler Moore Vision Initiative
MTM Vision Fall 2024 Symposium | Summation and Next Steps
- Lloyd Paul Aiello MD, PhD । Professor of Ophthalmology, Joslin Diabetes Center, Harvard Medical School
- S. Robert Levine, MD । Founder and CEO, MTM Vision Initiative
MTM Vision Fall 2024 Symposium | Communications, Collaborations and Fund Development
Moderator: Eric Carlson । Founder, The Carlson Company, Social Impact & Media, Award Winning Documentary and Film Producer: Public outreach, media relations, and fund development
Panelists
- Betsy Cote। Joslin Diabetes Center
- Chris Shoemaker । University of Michigan
- Maurine Slutzky । Stand Up to Cancer
- Sandy Puczynski, PhD । MTM Vision Lay Advisor
MTM Vision Fall 2024 Symposium | Consortium and Boehringer Ingelheim Collaboration
- Shelby Unsworth, PhD । Associate Director, Business Development, Michigan Medicine
- Marianne Laouri, PhD । Global Asset Lead, Retinal Health, Boehringer Ingelheim Pharmaceuticals
MTM Vision Fall 2024 Symposium | Special Guests
Will Flanary, MD and Kristin Flanary, MA – aka “Dr. Glaucomflecken” and “Lady Glaucomflecken.”
Will and Kristin Flanary share how their medical experiences led to the creation of their personas as Dr and Lady Glaucomflecken and their resulting advocacy work in eye health and co-survivorship, blending humor and education to raise awareness and promote change.
MTM Vision Fall 2024 Symposium | Future Directions
Moderator: Mark Pennesi, MD, PhD। Professor of Ophthalmology, School of Medicine, Oregon Health & Science University; Director, Ophthalmic Genetics at the Retina Foundation
Perspectives
- Rebecca Pfeiffer, PhD । Research Assistant Professor, Ophthalmology & Visual Science, John A. Moran Eye Center, University of Utah: Pathoconnectomics: Rewiring in Retinitis Pigmentosa.
- Rachel Huckfeldt, MD, PhD । Assistant Professor of Ophthalmology, Harvard Medical School, Fellowship Director, Inherited Retinal Degenerations Fellowship, Mass Eye & Ear: How has the consortium helped the field of IRDs and the importance to discovery of natural history studies which incorporate functional markers and endpoints.
Panelists
- James Weiland, PhD । University of Michigan
- Adriana Plevniak । MTM Vision Lay Advisor
MTM Vision Fall 2024 Symposium | Hot Topics
Facilitator: Chris German, PhD । Chair, MTM Vision Lay Advisory Committee
Perspectives
- Awareness Crisis in DRD: Paolo Silva, MD। Associate Professor of Ophthalmology, Joslin Diabetes Center, Harvard Medical School:
- Gait Assessment in the Evaluation of Functional Vision: Amanda Bicket, MD ।Assistant Professor, Ophthalmology and Visual Sciences, University of Michigan
- Developing a Patient-Reported Outcome (PRO) for DRD – Creating tools to capture patient voices: Fernanda (Maria) Abalem, MD, MSC, PhD । Faculty, University of Sao Paulo, Brazil
- Vitreous analysis for clinical assessment, staging, and patient selection for clinical trials: Jeffrey M. Sundstrom, MD, PhD । Associate Professor, Department of Cellular and Molecular Physiology, Neural and Behavioral Science, and Ophthalmology, Penn State University
MTM Vision Fall 2024 Symposium | Big Data and AI Approaches to Diabetic Retinal Disease
MTM Vision Update: S. Robert Levine, MD । Founder and CEO, MTM Vision
Perspectives
- Tien-en Tan, MBBS(Hons), MMed(Ophth), FRCOphth, FAMS । Clinical Assistant Professor, SingHealth Duke-NUS Ophthalmology & Visual Sciences Academic Clinical Program. Multi-modal AI for enhanced diagnosis, risk stratification and prognostication in DRD.
- Brian VanderBeek, MD, MPH, MSCE । Research to Prevent Blindness (RPB)-MTM Vision Physician Scientist Award Winner; Associate Professor of Ophthalmology, University of Pennsylvania. Use of real-world data for better understanding of DRD and population-level differences.
Panelists
- Chris German, PhD। Chair, MTM Vision Lay Advisory Committee
- Kerry Goetz, PhD। National Eye Institute
- Tunde Peto, MD, PhD। Queens University Belfast
MTM Vision Fall 2024 Symposium | Therapeutics Target Identification Through Human Tissue and Fluid ‘Omics
MTM Vision Update: Patrice Fort, PhD । Director, MTM Vision Ocular Biorepository & Resource Center
Perspectives
- Roger Cone, PhD । Mary Sue Coleman Director & Research Professor; Vice Provost and Director, U-M Life Sciences Institute; Professor, Department of Molecular & Integrative Physiology, U-M Medical School; Professor, Molecular, Cellular, and Developmental Biology, LSA. Process and resources for target identification and drug development.
- Przemyslaw (Mike) Sapieha, PhD । Founder & Chief Scientific Officer, SemaThera Inc. From target identification to drug development for ocular diseases.
Panelists
- Lloyd Paul Aiello, MD, PhD । Harvard Medical School
- Eric Ng, PhD | Eyebiotech Limited, a subsidiary of Merck & Co, Inc (Rahway, NJ)
- Subramaniam Pennathur, MD। University of Michigan
- Judy Hunt, MBA। MTM Vision Lay Advisor
MTM Vision Fall 2024 Symposium | Translating Science to Clinical Care for Diabetic Retinal Disease
MTM Vision Update: Jennifer Sun, MD, MPH । Science Co-Director, MTM Vision
Perspectives
- Aude Couturier, MD PhD। Professor of Ophthalmology, Paris Cité University; Deputy Head of the Ophthalmology Department, Lariboisière and Saint-Louis University Hospitals; Project leader EviRED (Evaluation Intelligente de la Rétinopathie Diabétique). Preliminary findings from EviRED natural history study.
- Malvina Eydelman, MD। Director of the Office of Health Technology Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices, Office of Product Evaluation and Quality, Food and Drug Administration, Maryland, USA. Food and Drug Administration Regulation of Medical Products for DRD
Panelists
- Michael Abramoff, MD, PhD। University of Iowa
- Jason McAnany, PhD। University of Illinois College of Medicine
- Sandy Puczynski, PhD । MTM Vision Lay Advisor
Boehringer Ingelheim Joins the Mary Tyler Moore Vision Initiative to Combat Vision Loss From Diabetes
Boehringer Ingelheim announces partnership with Mary Tyler Moore Vision Initiative to target diabetic retinal disease – November 12, 2024
November 15, 2024
By Sydney M Crago
This announcement establishes Boehringer as the first pharmaceutical company to join the MTM Vision Consortium.
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) have begun what is expected to be a long-term collaboration. This announcement establishes Boehringer as the first pharmaceutical company to join the MTM Vision Consortium.
The MTM Vision Consortium
The MTM Vision Consortium is working to unite innovators in the pre-competitive space from universities, foundations, as well as pharmaceutical and biotech companies. The consortium is housed at the University of Michigan. It hopes to lead international collaboration and is motivated by the urgency of millions of people worldwide who have lost or are at risk of losing their eyesight as a consequence of diabetes.1
The Consortium members share several goals:
- address the need for novel means to better diagnose and stage diabetic retinal diseases (DRDs)
- validate promising clinical trial endpoints and biomarkers, and
- accelerate the development of breakthrough therapies.
With these goals in mind, there is potential for treatment earlier in disease, before vision loss occurs, and to contribute to the creation of new regulatory pathways for drug approval.1
A new collaboration
Dr. Ulrike Graefe-Mody, Global Head of Retinal Health at Boehringer Ingelheim is quoted in the joint press release1 as saying, “We are excited to join forces with MTM Vision in leading a new era of vision preservation and protection for people living with diabetes. This collaboration will help us enhance our understanding of the progression of diabetic retinopathy and the role of retinal non-perfusion, supporting the development of our portfolio in diabetic retinal diseases. It also gives us access to a unique biospecimen bank, accelerating our research and biomarker identification. In return, we are openly sharing our current efforts for evidence generation to further understand DRD and support MTM Vision’s work. Together, we are setting a course to fundamentally change our understanding of vision loss from diabetes and how it is treated.”
Dr. S. Robert Levine, founder and CEO of MTM Vision provided an update on the news around the consortium, saying, “Here at our third Annual Global Symposium on curing vision loss from diabetes, which coincides with Diabetic Eye Disease Awareness Month, we are delighted to announce that Boehringer Ingelheim has joined us as a founding member of our MTM Vision Consortium. This Symposium provides a platform for the convening of global leaders dedicated to accelerating the development of innovative therapies to prevent and cure vision loss from diabetes. Boehringer Ingelheim’s commitment to our pre-competitive Consortium marks a pivotal moment along our path to ensure better patient outcomes by advancing research and sharing critical data. This will significantly strengthen our efforts to catalyze the development of new methods to diagnose and treat diabetic retinal disease earlier, which may preserve vision for millions of people at risk.”1
